Please visit answersincme.com/ZFZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of immunotherapy in neoadjuvant treatment of early breast cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for adding immunotherapy to chemotherapy in the neoadjuvant treatment of early HR-positive, HER2-negative breast cancer; Identify the clinical implications of the latest data for neoadjuvant treatment with immunotherapy plus chemotherapy regimens in early HR-positive, HER2-negative breast cancer; Describe the role that neoadjuvant, immunotherapy-containing regimens might play in the future management of patients with early HR-positive, HER2-negative breast cancer, including high risk patients.

Please visit answersincme.com/RKX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in skin cancer discusses strategies for adjuvant immunotherapy in resectable melanoma. Upon completion of this activity, participants should be better able to: Review the guideline-recommended role of adjuvant immunotherapy for the treatment of resectable melanoma; Describe the key adverse events associated with adjuvant immunotherapy for the treatment of resectable melanoma; Outline evidence-based, patient centric strategies to optimize the benefit-to-risk impact of adjuvant immunotherapy in resectable melanoma care

Please visit answersincme.com/GEU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the management of advanced basal cell carcinoma (BCC) with immunotherapies, based on the guidelines and clinical evidence. Upon completion of this activity, participants should be better able to: Review the guideline recommendations for the treatment of advanced BCC; Identify the clinical implications of the available evidence evaluating immunotherapy options for patients with advanced BCC; and Outline real-world considerations for the integration of immunotherapy into practice for the management of advanced BCC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/GWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck surgery discusses optimizing the in-practice use of neoadjuvant immunotherapy in the treatment of resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe clinical factors that should be considered when evaluating whether a patient with CSCC is a candidate for neoadjuvant immunotherapy; Review the clinical profiles of approved and emerging neoadjuvant immunotherapies for patients with resectable CSCC; and Outline practical considerations to optimize treatment outcomes for patients with resectable CSCC. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/BXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses B7-H3–directed antibody-drug conjugates as a treatment strategy for small-cell lung cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for developing antibody-drug conjugates (ADCs) targeting B7-H3 as treatment for extensive-stage small-cell lung cancer (ES-SCLC); Review the preliminary efficacy and safety data for emerging B7-H3–directed ADCs for the treatment of pretreated ES-SCLC; and Describe key clinical considerations for the future use of B7-H3–directed ADCs in ES-SCLC.

Please visit answersincme.com/TBW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer offers guidance for determining HER2 status in patients with advanced breast cancer, and shares insights on clinical data and strategies to optimize the use of antibody-drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Review the guideline recommendations to optimize the identification of patients with HER2-low advanced breast cancer; Outline the clinical implications of the most recent data evaluating the use of available ADCs in the treatment of HER2-low advanced breast cancer; and Identify practical strategies to optimize outcomes with ADC treatment for real-world patient populations with HER2-low advanced breast cancer.

Please visit answersincme.com/ZVJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the management of metastatic colorectal cancer (mCRC) discusses treatment strategies to enhance patient outcomes during later-line therapy. Upon completion of this activity, participants should be better able to: Identify guideline recommendations for later-line treatments for patients with mCRC; Describe recent evidence for later-line treatments for patients with mCRC, including evidence informing treatment sequencing; and Review evidence-based, patient-centered approaches to manage adverse events for patients with mCRC receiving later-line treatment.

Please visit answersincme.com/VWG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses patient selection and treatment for myelodysplastic syndromes. Upon completion of this activity, participants should be better able to: Identify practical strategies for risk stratification and mutation analysis of patients with myelodysplastic syndromes (MDS) to enable risk-adapted therapy; Review the clinical profiles of conventional and newly approved therapies to treat anemia in patients with lower-risk MDS; and Describe the impact of recent data on treatment practices for the management of anemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk MDS.

Please visit answersincme.com/CFN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in oncology discuss current and emerging treatments for unresectable stage I to III EGFR mutation–positive non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Review best practices for integrating biomarker testing into practice for stage I to III NSCLC; Describe the clinical profiles of current and emerging therapeutic approaches for the management of stage I to III NSCLC; and Outline multidisciplinary strategies to optimize the integration of a targeted approach into clinical practice for patients with stage I to III NSCLC.

Please visit answersincme.com/YSV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the practical implications of emerging TROP2 antibody–drug conjugates (ADCs) for the management of advanced or metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Discuss the rationale for targeting TROP2 in patients with advanced or metastatic NSCLC; Review the clinical profiles of emerging ADCs targeting TROP2 in patients with advanced or metastatic NSCLC; and Identify clinical strategies to optimize management of patients with advanced NSCLC treated with TROP2-directed ADCs, as they become available.